Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aspirin drug combo reduces dialysis risk

This article was originally published in The Tan Sheet

Executive Summary

Aspirin combined with the anti-platelet drug dipyridamole extends the life of artery-vein access grafts used for hemodialysis, according to a study of 649 participants with new AV grafts conducted by the Dialysis Access Consortium. The drug combination reduces loss of primary unassisted graph patency by 18 percent and the rate of developing significant stenosis by 28 percent, compared to a placebo, according to the National Institutes of Health. The release says most AVs fail because of clotting around blood vessels that narrow at the graft site





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts